Comparing Opiant Pharmaceuticals (OPNT) & Fission Uranium (FCUUF)

Share on StockTwits

Opiant Pharmaceuticals (NASDAQ:OPNT) and Fission Uranium (OTCMKTS:FCUUF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

4.8% of Opiant Pharmaceuticals shares are owned by institutional investors. 37.9% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


This table compares Opiant Pharmaceuticals and Fission Uranium’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals -449.52% -471.43% -190.80%
Fission Uranium N/A N/A N/A

Volatility & Risk

Opiant Pharmaceuticals has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Fission Uranium has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Opiant Pharmaceuticals and Fission Uranium, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 1 0 3.00
Fission Uranium 0 0 1 0 3.00

Opiant Pharmaceuticals presently has a consensus price target of $42.00, indicating a potential upside of 145.04%. Fission Uranium has a consensus price target of $2.00, indicating a potential upside of 271.54%. Given Fission Uranium’s higher probable upside, analysts clearly believe Fission Uranium is more favorable than Opiant Pharmaceuticals.

Earnings & Valuation

This table compares Opiant Pharmaceuticals and Fission Uranium’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $18.45 million 2.77 $6.58 million $2.94 5.83
Fission Uranium N/A N/A -$7.80 million N/A N/A

Opiant Pharmaceuticals has higher revenue and earnings than Fission Uranium.


Fission Uranium beats Opiant Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

About Fission Uranium

Fission Uranium Corp. engages in the exploration and development of uranium properties in Canada. Its primary asset is the 100% owned Patterson Lake South property that consists of 17 contiguous mineral claims covering an area of 31,039 hectares located in the Athabasca Basin region of Saskatchewan. The company was incorporated in 2013 and is headquartered in Kelowna, Canada.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply